CRITICS-II: A multicentre randomized phase II trial of neo‐adjuvant chemotherapy followed by surgery vs. neo‐adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs. neo‐adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503248-15-00

Acronym

M15CRI

Enrollment

207

Registered

2024-06-18

Start date

2017-10-09

Completion date

Unknown

Last updated

2025-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with TNM 8th ed stage IB-IIC gastric adenocacinoma

Brief summary

Event‐free survival at 1 year after randomisation (events: local recurrence, regional recurrence, local‐regional recurrence or progression, distant recurrence, or death from any cause).

Interventions

DRUGCAPECITABINE

DRUGOXALIPLATIN

DRUGCARBOPLATIN

DRUGPACLITAXEL

DRUGDOCETAXEL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Event‐free survival at 1 year after randomisation (events: local recurrence, regional recurrence, local‐regional recurrence or progression, distant recurrence, or death from any cause).	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026